Clinically, some studies have shown that patients with JAK2 exon 12 mutations are younger and present with erythrocytosis, but have similar symptoms and rates of survival when compared to patients with JAK2 V617F mutations [48]. The gene discussed is JAK2; the disease is polycythemia.